A recent Perspective in Nature Communications , “The hidden risks of CRISPR/Cas: structural variations and genome integrity” (August 5, 2025), emphasizes a growing concern in gene editing: while CRISPR technology enables powerful genomic interventions, unintended outcomes—such as kilobase- to megabase-scale deletions, chromosomal translocations, and broader structural variations (SVs)—pose serious safety and regulatory challenges Nature . These risks are especially pronounced as therapeutic genome editing advances toward clinical applications.